Plain-English translation of NCT05742607 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining two immunotherapy medications—IPH5201 and durvalumab—with standard chemotherapy can help treat early-stage non-small cell lung cancer more effectively. You would receive this medication combination before surgery to shrink your tumor, then have surgery to remove it. For some participants, the treatment may continue after surgery as well.
Current treatments for early-stage lung cancer don't work for everyone, and doctors want to see if adding these newer immunotherapy drugs to chemotherapy can improve survival and reduce the chance that cancer comes back.
You likely qualify if…
You likely don't qualify if…
You would visit the study center regularly to receive the medication combination (IPH5201, durvalumab, and chemotherapy) over several weeks before your scheduled lung surgery. After surgery, depending on which group you're in, you may continue receiving some of these medications for additional months. You'll have regular blood tests, imaging scans, and check-ins with your doctor to monitor how well the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States